Organization
Radius Pharmaceuticals
7 clinical trials
Clinical trial
A Multicenter, Open-Label, Flexible Dose Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Patients With Treatment-Resistant Childhood Absence SeizuresStatus: Terminated, Estimated PCD: 2019-06-24
Clinical trial
A Multicenter, Open-Label Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi SyndromeStatus: Terminated, Estimated PCD: 2019-07-31
Clinical trial
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi SyndromeStatus: Terminated, Estimated PCD: 2022-10-06
Clinical trial
A Phase 2, Open-label, Dose-finding Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Patients With Treatment-Resistant Childhood Absence SeizuresStatus: Terminated, Estimated PCD: 2019-05-15
Clinical trial
A Phase 3, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi SyndromeStatus: Withdrawn, Estimated PCD: 2025-08-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi SyndromeStatus: Terminated, Estimated PCD: 2019-07-17
Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution as Adjunctive Therapy With Vigabatrin as Initial Therapy in Patients With Infantile SpasmsStatus: Terminated, Estimated PCD: 2019-05-29